Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)

Next Previous
Trial Profile

Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 18 Nov 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 12 Nov 2020 Results (n=108) of analysis assessing pharmacokinetic profiles of risperidone and 9-hydroxy (OH)-risperidone and how these related to treatment emergent extrapyramidal side effects published in the British Journal of Psychiatry
  • 17 Oct 2017 Results of post hoc analysis (n=371) assessing placebo effects in the treatment of noncognitive symptoms of alzheimer's disease, were published in the Journal of Clinical Psychiatry.
  • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top